Jane Street
RIGL icon

Jane Street’s Rigel Pharmaceuticals RIGL Stock Holding History

Jane Street’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Sell
7,300
-8,200
-53% -$253K ﹤0.01% 9322
2026
Q1 		$419K Sell
15,500
-15,600
-50% -$524K ﹤0.01% 8462
2025
Q4 		$1.33M Buy
31,100
+15,900
+105% +$599K ﹤0.01% 5558
2025
Q3 		$431K Buy
+15,200
New +$455K ﹤0.01% 8173
2022
Q3 		– Sell
-4,200
Closed -$47K – 10329
2022
Q2 		$47K Buy
+4,200
New +$84.4K ﹤0.01% 8943
2022
Q1 		– Sell
-2,450
Closed -$65K – 10919
2021
Q4 		$65K Sell
2,450
-10,890
-82% -$329K ﹤0.01% 9434
2021
Q3 		$484K Buy
13,340
+7,020
+111% +$276K ﹤0.01% 7342
2021
Q2 		$274K Buy
+6,320
New +$239K ﹤0.01% 8310

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's RIGL Position: Q2 2026 in Review

Jane Street sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 70,208 shares — an estimated $2.17M sold.

Jane Street first reported a position in RIGL in Q2 2013 and held it in 33 quarters. The position peaked at $11.8M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Jane Street reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 70,208 Rigel Pharmaceuticals shares in Q2 2026, an estimated $2.17M.
  • Jane Street first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Jane Street's Rigel Pharmaceuticals position peaked at $11.8M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.